{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:42:21Z","timestamp":1783759341713,"version":"3.55.0"},"reference-count":49,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Enthesitis is a key pathological and clinical feature of psoriatic arthritis (PsA) in children and adults. Enthesitis is typically assessed clinically using several validated enthesitis scoring systems that have been used in clinical trials. Enthesitis treatment response has been reported as change in the total enthesitis score or the proportion of patients who achieved complete resolution. The majority of trials in PsA did not require patients to have enthesitis at study entry since enthesitis was evaluated only as a secondary outcome. Despite the inherent limitations of the clinical assessment of enthesitis, imaging of the entheses using ultrasound or magnetic resonance imaging has rarely been used in clinical trials to assess response to treatment of enthesitis. This systematic review summarizes existing evidence regarding pharmaceutical and nonpharmaceutical interventions for enthesitis in patients with PsA to facilitate an evidence-based update of the Group for Research and Assessment in Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for PsA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a systematic literature review to identify 41 randomized clinical trials that reported enthesitis treatment response in patients with PsA. For each intervention, the response effect size was summarized and the quality of evidence was graded. Recommendations were then formulated for the various pharmacological and nonpharmacological therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 41 randomized clinical trials in our review and graded each intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Several classes of systemic conventional and advanced therapies and local measures were recommended for active enthesitis in patients with PsA.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.220312","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T12:16:16Z","timestamp":1667304976000},"page":"258-264","source":"Crossref","is-referenced-by-count":19,"title":["Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations"],"prefix":"10.3899","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-1715","authenticated-orcid":false,"given":"Lihi","family":"Eder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2061-2042","authenticated-orcid":false,"given":"Ashish J.","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9254-6171","authenticated-orcid":false,"given":"Philippe","family":"Carron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Bertheussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-0573","authenticated-orcid":false,"given":"Juan D.","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3849-0100","authenticated-orcid":false,"given":"May","family":"Azem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7379-4732","authenticated-orcid":false,"given":"Andrea Delle","family":"Sedie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-3148","authenticated-orcid":false,"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6855-2413","authenticated-orcid":false,"given":"Roberto","family":"Ranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0589-8740","authenticated-orcid":false,"given":"Ashley","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Turkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5912-1689","authenticated-orcid":false,"given":"Ricardo Acayaba","family":"de Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2256-9068","authenticated-orcid":false,"given":"Hulya","family":"Bukulmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2107-8846","authenticated-orcid":false,"given":"Maria S.","family":"Stoenoiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5669-7917","authenticated-orcid":false,"suffix":"II","given":"Arthur M.","family":"Mandelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3579-5574","authenticated-orcid":false,"given":"Michaela","family":"Koehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris A.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"2023020105301814000_50.2.258.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.188"},{"key":"2023020105301814000_50.2.258.2","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/acr.23174","article-title":"Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2023020105301814000_50.2.258.3","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/acr.23249","article-title":"Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"69","author":"Mease","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2023020105301814000_50.2.258.4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13075-017-1399-5","article-title":"The association between sonographic enthesitis and radiographic damage in psoriatic arthritis","volume":"19","author":"Polachek","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2023020105301814000_50.2.258.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210242"},{"key":"2023020105301814000_50.2.258.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160387"},{"key":"2023020105301814000_50.2.258.7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2023020105301814000_50.2.258.8","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.39700","article-title":"The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023020105301814000_50.2.258.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386"},{"key":"2023020105301814000_50.2.258.10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/acr.23693","article-title":"Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: a prospective cohort study","volume":"71","author":"H\u00f8jgaard","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2023020105301814000_50.2.258.11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000486"},{"key":"2023020105301814000_50.2.258.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203073"},{"key":"2023020105301814000_50.2.258.13","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino M , Schett G , L\u00f3pez-Rdz A , Secukinumab significantly decreased joint synovitis measured by power doppler ultrasonography in biologic-na\u00efve patients with active psoriatic arthritis: primary (12-week) results from a randomized, placebo-controlled phase III study [abstract]. Arthritis Rheumatol 2020;72 (suppl 10).","DOI":"10.1093\/rheumatology\/keab247.182"},{"key":"2023020105301814000_50.2.258.14","unstructured":"Behrens F , Sewerin P , De Miguel E , Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the achilles tendon: 52-weeks results from a randomized, placebo-controlled phase 3b trial [abstract]. Arthritis Rheumatol 2020;72 (suppl 10)."},{"key":"2023020105301814000_50.2.258.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140878"},{"key":"2023020105301814000_50.2.258.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"2023020105301814000_50.2.258.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211568"},{"key":"2023020105301814000_50.2.258.18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000669"},{"key":"2023020105301814000_50.2.258.19","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology"},{"key":"2023020105301814000_50.2.258.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"2023020105301814000_50.2.258.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2023020105301814000_50.2.258.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32483-8"},{"key":"2023020105301814000_50.2.258.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.6727"},{"key":"2023020105301814000_50.2.258.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"2023020105301814000_50.2.258.25","doi-asserted-by":"crossref","unstructured":"Mease P , Deodhar A , van der Heijde D , Efficacy and safety of deucravacitinib (BMS-986165), an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, double-blind, placebo-controlled trial [abstract]. Arthritis Rheumatol 2020;72 (suppl 10).","DOI":"10.1136\/annrheumdis-2021-eular.2603"},{"key":"2023020105301814000_50.2.258.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2023020105301814000_50.2.258.27","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023020105301814000_50.2.258.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210775"},{"key":"2023020105301814000_50.2.258.29","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT Study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023020105301814000_50.2.258.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"2023020105301814000_50.2.258.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"2023020105301814000_50.2.258.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"2023020105301814000_50.2.258.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2023020105301814000_50.2.258.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2023020105301814000_50.2.258.35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2023020105301814000_50.2.258.36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2023020105301814000_50.2.258.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687"},{"key":"2023020105301814000_50.2.258.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"2023020105301814000_50.2.258.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30952-8"},{"key":"2023020105301814000_50.2.258.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"2023020105301814000_50.2.258.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210724"},{"key":"2023020105301814000_50.2.258.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216500"},{"key":"2023020105301814000_50.2.258.43","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"2023020105301814000_50.2.258.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00347-5"},{"key":"2023020105301814000_50.2.258.45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/03009742.2017.1287304","article-title":"Beneficial effect of n-3 polyunsaturated fatty acids on inflammation and analgesic use in psoriatic arthritis: a randomized, double blind, placebo-controlled trial","volume":"47","author":"Kristensen","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"2023020105301814000_50.2.258.46","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/acr.23614","article-title":"Impact of high-intensity interval training on disease activity and disease in patients with psoriatic arthritis: a randomized controlled trial","volume":"71","author":"Thomsen","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2023020105301814000_50.2.258.47","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2023020105301814000_50.2.258.48","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","article-title":"Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis","volume":"11","author":"Armstrong","year":"2021","journal-title":"Dermatol Ther"},{"key":"2023020105301814000_50.2.258.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.08.006"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.220312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T13:39:39Z","timestamp":1675258779000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.220312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,1]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.3899\/jrheum.220312"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.220312","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}